SCHD's $250,000 Projection: The Math Is Easy. The Assumptions Are Not.

Here's the headline doing the rounds: invest $50 a week in the Schwab U.S. Dividend Equity ETF (SCHD) for 20 years, and you'll have over $250,000 with roughly $72,000 in dividend income.

The math checks out. $50 a week is $2,600 a year. Over 20 years that's $52,000 in contributions. If SCHD continues to deliver its historical average annual return of about 13.2% with dividends reinvested, the compound growth takes that $52,000 to somewhere in the $250,000 range. A calculator says so. An independent DRIP simulator on the same inputs shows roughly $239,621.

The math is arithmetic. The assumptions inside it are the thing that matters.

SCHD's 10-year track record is exceptional. It's also behind you.

SCHD has returned 13.17% annualized over its 10-year history and 13.66% since inception in October 2011. It returned 29.53% over the trailing year. It's up 22.79% year-to-date through September 2026. The fund tracks the Dow Jones U.S. Dividend 100 Index, which screens roughly 100 U.S. companies for dividend yield, return on equity, free cash flow to total debt, and a track record of raising dividends. The result is a portfolio tilted toward healthcare, energy, financials, and consumer staples.

The fund currently holds $112.8 billion in assets, with 102 positions weighted by market cap. Top holdings: Merck at 4.9%, Abbott Labs at 4.5%, Amgen at 4.3%, Coca-Cola at 4.3%, and Chevron at 4.3%. Healthcare alone is 21.3% of the fund.

Here's what the projection articles don't show you: SCHD's historical return is exactly that — historical. It ran from a period of ultra-low interest rates, a bull market from 2013 through 2021, and a 3-for-1 stock split in October 2024 that made the shares cheaper without changing the underlying economics. The 13.2% figure compresses all of that into one number and then projects it straight ahead for two decades.

That's not how investing works. It's how calculators do.

The dividend itself is shrinking.

This is the number the projection articles bury. SCHD's quarterly dividend has been declining over the past year and a half. The most recent Q2 2026 payout was $0.2525 per share. That's down from $0.2782 in Q4 2025, down from $0.2604 in Q3 2025, and a fraction of the $0.7545 and $0.8241 payouts in Q3 and Q2 2024 — which look enormous until you account for the stock split that roughly tripled the share count.

Even adjusting for the split, the dividend growth story has stalled. The DRIPCalc data shows SCHD's 1-year dividend CAGR at -2.69% and its 2-year CAGR at -4.03%. The 5-year figure sits at 7.06%. The 10-year average is 9.22%, but that's anchored to the explosive early years of the fund.

The current TTM dividend yield sits at 3.11%. That's a decent yield. It's not a yield that grows at 9% every year forever. Anyone building a 20-year projection on that kind of dividend acceleration is projecting past the data, not through it.

What you'd actually need for that $250,000

Let me decompose what the $250,000 projection requires:

• $52,000 in your own contributions over 20 years
• A total annualized return of roughly 12-13% from SCHD, every year for two decades, with all dividends reinvested

That 12-13% return would need to come from two sources: dividend yield (currently ~3.1%) plus share price appreciation, with dividend growth feeding the total return when dividends are reinvested. A simple arithmetic decomposition of a 13.2% annualized total return into roughly 3.2% from yield leaves roughly 10% to come from share price appreciation and dividend growth combined — not 9-10% of price gains on top of a sustained dividend rise.

Compare that to the broader market. The S&P 500, as proxied by SPY, is yielding just 1.24% and returned 15.02% over the trailing year. SCHD's current yield advantage is real — nearly 3% vs. 1.2% — but the S&P 500's forward P/E of roughly 19 suggests it's not exactly cheap either. Neither fund is a fat pitch at these levels.

The 13.2% historical return that the projection assumes is real. But it's also the past. The S&P 500 has returned about 10% annualized over the last century. SCHD's 10-year run is above that average. Projecting above-average returns for the next 20 years because the last 10 were above average is the most common mistake investors make.

The structure works in your favor. The projections don't.

Here's where SCHD actually earns its place in a conversation about long-term investing. The index methodology matters more than any projection calculator. The Dow Jones U.S. Dividend 100's financial health screens — free cash flow to debt, ROE, five-year dividend history — mean SCHD is constantly filtering out companies that get bloated or leveraged. The annual March reconstitution rebuilds the portfolio from scratch. Stocks that no longer meet the criteria get cut. This is a self-cleaning mechanism that most broad index funds don't have.

The 0.06% expense ratio is essentially free. The fund has $112.8 billion in assets but charges less than six basis points a year. Over 20 years that costs you $312 on every $52,000 you invest. Not a meaningful drag.

The tax cost ratio over 10 years is 1.05%, which is lower than the large-value category average of 1.70%. The post-liquidation 10-year return of 10.03% vs. the category's 8.65% shows the fund doesn't just earn returns — it keeps more of them after taxes.

The risk section they leave out

• SCHD's worst three-month period was a 21.55% drawdown in early 2020. That's the kind of hole you need to survive mentally over a 20-year holding period.
• The fund's concentration in the top 10 holdings (about 42% of assets) means a handful of names move the needle. Healthcare at 21.3% is real exposure to drug pricing, patent cliffs, and regulatory risk.
• The current dividend decline could be a temporary misalignment during a reconstitution cycle. Or it could signal that the index's yield screen is pulling in companies that are under more pressure. Either way, it contradicts the "dividend growth at 9% forever" assumption baked into the most optimistic projections.
• SCHD is up 22.79% year-to-date. It's near its 52-week high of $35.31. Buying a 20-year position at the top of a 23% year means you're starting from the expensive end of the recent range. That doesn't matter in 20 years if the underlying companies compound, but it matters for your first 2-3 years.

What to do with the number instead

Here's what the $250,000 projection is actually useful for: it shows you the scale of the compounding gap between $52,000 in contributions and $250,000 in ending value. That $198,000 difference is everything — it's the return on your return on your return. It's the reason time in the market beats timing the market.

The question isn't whether $50 a week in SCHD could get you there. The math says it could. The question is whether the 12-13% annualized return the math assumes is the right expectation going forward, and whether you're comfortable with a fund whose dividend has recently declined, whose top holdings are concentrated in healthcare and energy, and whose biggest wins came behind you.

If you're going to set up that weekly investment, set it up for the 20-year horizon, not the calculator's headline. Set it up and then forget the number the internet told you it would produce. The actual result will be determined by the companies SCHD holds in 2028, 2033, and 2041 — companies you don't know yet because the annual reconstitution will have already changed the portfolio five or six times.

That's the honest version of the math. The $250,000 figure is an illustration of compounding, not a target. Treat it that way.